Ananda Developments Plc (AQSE: ANA), a developer of cannabinoid medicines, has secured the necessary funding to initiate a trial to test the effectiveness of its cannabidiol oil, MRX1, in treating
Ananda Developments (AQSE:ANA) First Cannabinoid Medicines Launched
Ananda’s ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
Company Profile (AQSE:ANA) Ananda Developments
Ananda Developments (AQSE: ANA) is an AQUIS-listed healthcare company involved in the development of cannabinoid-based medicines with two concurrently running, third-party funded, Phase II randomised control trials (RCTs).
Zak Mir talks to Melissa Sturgess, CEO Ananda Developments
In the wake of the MRX Global acquisition, and what this means for the medical cannabis group
Ananda Developments Plc (ANA.L) Grant of Home Office Licence
The Directors of Ananda announce the following progress regarding Ananda’s vision to become a significant participant in the emerging medicinal cannabis sector: